# Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

> **NCT06856577** · PHASE3 · RECRUITING · sponsor: **Adverum Biotechnologies, Inc.** · enrollment: 284 (estimated)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)
- Wet AMD

## Interventions

- **GENETIC:** Ixo-vec
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT06856577
- **Lead sponsor:** Adverum Biotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-28
- **Primary completion:** 2026-12-22
- **Final completion:** 2030-11-23
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06856577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06856577, "Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06856577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*